Proton therapy in the management of non-Hodgkin lymphoma

被引:14
|
作者
Sachsman, Suzanne [1 ]
Flampouri, Stella [1 ]
Li, Zuofeng [1 ]
Lynch, James [2 ]
Mendenhall, Nancy P. [1 ]
Hoppe, Bradford S. [1 ]
机构
[1] Univ Florida, Proton Therapy Inst, 2015 Jefferson St, Jacksonville, FL 32206 USA
[2] Univ Florida, Coll Med, Dept Hematol & Oncol, Gainesville, FL USA
关键词
Lymphoma and Hodgkin disease; radiation; outcomes; proton beam therapy; B-CELL LYMPHOMA; MODULATED RADIATION-THERAPY; ORBITAL LYMPHOMA; MEDIASTINAL LYMPHOMA; RADIOTHERAPY;
D O I
10.3109/10428194.2015.1014364
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Proton therapy (PT) is a highly conformal type of radiation therapy that can target the tumor while sparing dose to surrounding normal tissues. This study reviews a single institution's experience managing patients with non-Hodgkin lymphoma (NHL) treated with PT. Eleven patients with NHL were treated with PT from January 2008 to January 2014 on an institutional review board-approved outcomes tracking protocol, and included patients with indolent orbital lymphoma (n = 4), primary mediastinal B-cell lymphoma (n = 3), plasmablastic lymphoma (n = 2) and natural killer (NK) T-cell lymphoma (n = 2). The median followup was 38 months. The 2-year rate of local control was 91%, with one patient with NK T-cell lymphoma having recurrence in-field. Toxicities were limited to grade 2 at highest, during follow-up. PT is a feasible and effective treatment for NHL. Early outcomes are favorable. Longer follow-up and more patients are needed to confirm our findings.
引用
收藏
页码:2608 / 2612
页数:5
相关论文
共 50 条
  • [1] Non-Hodgkin lymphoma therapy landscape
    Chaudhari, Kritika
    Rizvi, Salman
    Syed, Basharut A.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (09) : 663 - 664
  • [2] Therapy of non-Hodgkin's lymphoma
    Coffey, J.
    Hodgson, D. C.
    Gospodarowicz, M. K.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (Suppl 1) : S28 - S36
  • [3] New therapy for non-Hodgkin lymphoma
    Crawford, LM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (13): : 1640 - 1640
  • [4] Non-Hodgkin lymphoma therapy landscape
    Kritika Chaudhari
    Salman Rizvi
    Basharut A. Syed
    [J]. Nature Reviews Drug Discovery, 2019, 18 : 663 - 664
  • [5] CONTROVERSIES IN THE MANAGEMENT OF NON-HODGKIN LYMPHOMA
    ENGERT, A
    DIEHL, V
    [J]. EUROPEAN JOURNAL OF CANCER, 1991, 27 (03) : 309 - 315
  • [6] Therapy of indolent non-Hodgkin lymphoma
    Seiler, T.
    Herfarth, K.
    Klapper, W.
    Dreyling, M.
    [J]. ONKOLOGE, 2014, 20 (10): : 1028 - 1038
  • [7] Therapy of non-Hodgkin's lymphoma
    J. Coffey
    D. C. Hodgson
    M. K. Gospodarowicz
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30 : S28 - S36
  • [8] Rituximab for the therapy of non-Hodgkin's lymphoma
    Rummel, M. J.
    [J]. ONKOLOGE, 2007, 13 (03): : 227 - +
  • [9] PROGNOSIS AND THERAPY OF NON-HODGKIN LYMPHOMA IN CHILDREN
    KUHNER, U
    BLEHER, EA
    GRETILLAT, P
    DELALIEU, B
    PEDRINIS, E
    WAGNER, HP
    [J]. MONATSSCHRIFT KINDERHEILKUNDE, 1977, 125 (05) : 461 - 462
  • [10] Immune and Cell Therapy in Non-Hodgkin Lymphoma
    Merryman, Reid W.
    Houot, Roch
    Armand, Philippe
    Jacobson, Caron
    [J]. CANCER JOURNAL, 2020, 26 (03): : 269 - 277